Inflammation in cardiovascular disease cart, horse or both-revisited

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 10, 2002, Pages 1514-1515

  Tracy, Russell P ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION;

EID: 0036791532     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000035403.39442.DB     Document Type: Editorial

References (22)

1. Kipling R. The conundrum of workshops. In: Modern British Poetry. Untermeyer L, ed. New York, NY: Bartleby, 1999.
2. Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation. 1998;97:2000-2002.
3. Altman L. Doctors who examined Bush say he is exceptionally fit. New York Times. August 7, 2002:A15.
4. Bermudez EA, Rifai N, Buring J, Manson JAE, Ridker PM. Interrelationship among circulating interleukin-6 C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002;22:1668-1673.
5. Buring J, Hennekens C. The Women's Health Study: summary of the study design. J Myocard Ischemia. 1992;4:27-29.
6. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-978.
7. Tracy R, Macy E, Bovill E, Cushman M, Psaty B, Cornell E, Kuller L. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17:2167-2176.
8. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study [see comments]. BMJ. 1996;312:1061-1065.
9. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209-214.
10. Wooltorton E. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex). CMAJ. 2002;166:1692-1693.
11. de'Clari F, Salani I, Safwan E, Giannacco A. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation. 2002;105:E183.
12. Grundy SM, Bazzarre T, Cleeman J, D'Agostino RB Sr, Hill M, Houston-Miller N, Kannel WB, Krauss R, Krumholz HM, Lauer RM, Ockene IS, Pasternak RC, Pearson T, Ridker PM, Wood D. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment-Writing Group I. Circulation. 2000;101:E3-E11.
13. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction [see comments]. Circulation. 1998;97:2007-2011.
14. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
15. Paterson JM, Llewellyn-Thomas HA, Naylor CD. Using disease risk estimates to guide risk factor interventions: field test of a patient workbook for self-assessing coronary risk. Health Expect. 2002;5:3-15.
16. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992;35:982-984.
17. Macy E, Hayes T, Tracy R. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin Chem. 1997;43:52-58.
18. Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4 producing CD4+ T cells. J Exp Med. 1997;185:461-469.
19. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96-102.
20. Walsh BW, Cox DA, Sashegyi A, Dean RA, Tracy RP, Anderson PW. Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. Am J Cardiol. 2001;88:825-828.
21. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost. 2001;85:619-625.
22. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.